A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Clinical trial NCT01657682 · COMPLETED

Trial details

NCT number: NCT01657682
Sponsor: Arog Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

Start date: 2012-10-01
Primary completion: 2019-04-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.